Evaluation of levels of physical activity, resilience and depression in chronic renal patients submitted to hemodialysis

Abstract

Introduction: Major Depressive Disorder (MDD) is a profound picture of loss of well-being and mental health of many individuals around the world, where Brazil ranks second in the highest number of depressed people in America. However, the treatment of MDD is a challenge for medicine, as it is long and the drugs used have high adverse effects and high costs. In order to get around this problem, discussions about the potential of psilocybin, a hallucinogenic substance extracted from mushrooms of the genus Psilocybe, in the treatment of TDM have resurfaced. Objective: This study aimed to evaluate the potential of psilocybin in the treatment of MDD. Methodology: A literature review was carried out with documents published between 2012-2022 in PubMed, Web of Science, CAPES and Scielo databases. After applying the inclusion and exclusion criteria, 29 works were selected that served as a basis for the discussion of the pharmacological activities, therapeutic uses, adverse effects, toxicity and mechanism of action of psilocybin when applied to treat MDD. Results: Psilocybin improved the quality of life of patients in the short and long term, with a decrease in depressive symptoms from the first week onwards, with doses ranging from 0.3 to 30 mg/kg. The therapeutic efficacy of psilocybin proved to be more persistent in comparison with commonly used psychedelics and without harmful effects due to prolonged use. Conclusion: Psilocybin has shown to be a promising agent for the treatment of depression. However, it is essential to conduct more robust studies regarding the analysis of possible drug interactions.